Suchergebnisse - "Curtin, Nicola"

PubPharm (29)

1

Strategies Employed for the Development of PARP Inhibitors

enthalten in: Methods in molecular biology (Clifton, N.J.) | 2017

von Canan, S. | Maegley, K. | Curtin, N.

2

Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself

enthalten in: PloS one | 2015

von McCrudden, C. | O'Rourke, M. | Cherry, K. | +14

3

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma

enthalten in: Current opinion in oncology | 2014

von Vormoor, B. | Curtin, N.

4

Therapeutic applications of PARP inhibitors : anticancer therapy and beyond

enthalten in: Molecular aspects of medicine | 2013

von Curtin, N. | Szabo, C.

5

Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers : sensitivity to PARP inhibitors, platinum, and survival

enthalten in: Cancer research | 2012

von Mukhopadhyay, A. | Plummer, E. | Elattar, A. | +8

6

Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K

enthalten in: Molecular cancer therapeutics | 2012

von Munck, J. | Batey, M. | Zhao, Y. | +15

7

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2

enthalten in: Journal of the National Cancer Institute | 2011

von Drew, Y. | Mulligan, E. | Vong, W. | +9

8

The use of PARP inhibitors in cancer therapy : use as adjuvant with chemotherapy or radiotherapy; use as a single agent in susceptible patients; techniques used to identify susceptible patients

enthalten in: Methods in molecular biology (Clifton, N.J.) | 2011

von Shall, S. | Gaymes, T. | Farzaneh, F. | +2

9

Strategies employed for the development of PARP inhibitors

enthalten in: Methods in molecular biology (Clifton, N.J.) | 2011

von Canan, S. | Maegley, K. | Curtin, N.

10

Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials

enthalten in: Cancer chemotherapy and pharmacology | 2010

von Zaremba, T. | Thomas, H. | Cole, M. | +2